- Details
- Daniel Barocas joins Alicia Morgans in a conversation on the prospective population-based Comparative Effectiveness Analysis of Surgery And Radiation (CEASAR) study which assess rates and predictors of patient-reported treatment regret among men deciding on treatment for localized prostate cancer. The CEASAR Study began accruing patients in 2010 and has a population-based cohort of almost 3000 men...
|
- Details
- Laurence Klotz joins Phillip Koo at the 13th International Uro-Oncology Congress in São Paulo, Brazil in a discussion on Active Surveillance (AS), High-intensity focused ultrasound (HIFU), and focal therapy in Latin America and developing countries. There are challenges with active surveillance in developing countries that might not have formal prostate cancer screening programs, a lack of resourc...
|
- Details
- Alicia Morgans is joined by Stacy Loeb to discuss her presentation at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium on the risks and the benefits of active surveillance in the intermediate-risk population. Over the last several years, there has been an increase in the utilization of active surveillance in the United States for patients with intermediate r...
|
- Details
- The Scientific Director at the Society of Oncology and Hematology from del Cesar, Columbia, Ray Manneh Kopp joins Phillip Koo bringing a global perspective to a discussion on the novel approaches in the management of high-risk prostate cancer. They discuss the diagnosis criteria currently being used, the novelties in the diagnosis, and adjuvant alternatives in this disease. Biographies: Ray Manneh...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss MARCAP, a meta-analysis of randomized trials in cancer of the prostate. This individual patient data meta-analysis of relevant randomized trials aimed to quantify the benefit of various androgen deprivation therapy (ADT) intensification strategies in men receiving radiotherapy for the treatment of prostate cancer in aggregate and in clinically releva...
|
- Details
- Paul Nguyen discusses a groundbreaking paper on health equity in prostate cancer with its authors, Bhav Jain and Christopher Dee. The paper focuses on racial disparities in treatment delays among younger men with prostate cancer. Utilizing the National Cancer Database, the study reveals that young Black men experience treatment delays more frequently than their older Black or White counterparts. T...
|
- Details
- Matthew Cooperberg joins Charles Ryan in a discussion on risk-stratified therapy for localized prostate cancer discussing who the patient is that should get active surveillance (AS) vs who shouldn't. To begin their conversation, Dr. Cooperberg previews the latest data coming from the AUA Quality Registry (AQUA) on the percentage of patients receiving active surveillance. This full data will be pre...
|
- Details
- Alicia Morgans and Michael Brooks discuss a recent manuscript entitled, “Validating the Association of Adverse Pathology with Distant Metastasis and Prostate Cancer Mortality 20-years After Radical Prostatectomy”. Dr. Brooks goes into depth on how adverse pathology correlates with long-term prostate cancer outcomes. They also discuss active surveillance for low-risk patients and how to stratify th...
|
- Details
- Alicia Morgans and Eric Klein discuss two papers that involve a unique cohort of patients with early-stage prostate cancer. Dr. Klein details the use of the Oncotype GPS score to stratify patients and determine who is safe for active surveillance. They also discuss how to use MRI histology, adverse pathology, and genomic profiling systems together. They discuss advising clinicians on how to start...
|
- Details
- In this conversation with Alicia Morgans, Daniel Spratt discusses artificial intelligence (AI)-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy (ADT) in localized prostate cancer with validation in NRG/RTOG 9408. The current standard of care for men with intermediate- and high-risk localized prostate cancer treated with radiotherapy is the addition o...
|